The association of metabolic syndrome and psoriasis: A population- and hospital-based cross-sectional study

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 3, 2015, Pages 490-497

  Miller, I M ^a,b   Ellervik, C ^c   Zarchi, K ^a   Ibler, K S ^a   Vinding, G R ^a   Knudsen, K M ^d   Jemec, G B ^a,b  

^a ROSKILDE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NAESTVED HOSPITAL   (Denmark)

^d LEO PHARMA A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL OBESITY; ADULT; ARTICLE; BLOOD SAMPLING; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PHYSICAL EXAMINATION; POPULATION; PRIORITY JOURNAL; PSORIASIS; SELF REPORT; AGED; COMPLICATION; HOSPITAL; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 84923109016     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12595     Document Type: Article

References (18)

1. Li K, Armstrong AW,. A review of health outcomes in patients with psoriasis. Dermatol Clin 2012; 30: 61-72.
2. Grundy SM, Brewer HB Jr, Cleeman JI, et al,. Definition of Metabolic Syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004; 24: e13-e18.
3. Miller IM, Jemec CBE,. Maturation of an idea: a historical perspective on the association of psoriasis with the metabolic syndrome and cardiovascular disease. Arch Dermatol. 2012; 148: 112.
4. Miller IM, Ellervik C, Yazdanyar S, et al,. Meta-analysis of psoriasis and cardiovascular disease, and associated risk factors. J Am Acad Dermatol 2013; 69: 1014-1024.
5. Miller IM, Skaaby T, Ellervik C, et al,. Quantifying cardiovascular risk factors in patients with psoriasis: a meta-analysis. Br J Dermatol 2013; 169: 1180-1187.
6. Bergholdt HK, Bathum L, Kvetny J, et al,. Study design, participation and characteristics of the Danish General Suburban Population Study. Dan Med J 2013; 60: A4693.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
8. Alberti KG, Eckel RH, Grundy SM, et al,. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
9. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-1334.
10. Institute for rational Pharmacotherapy in Denmark. Guidelines on Diabetes. Månedsbladet Rationel Farmakoterapi. 2006; 8. www.irf.dk (last accessed: 21 May 2014)
11. Chobanian AV, Bakris GL, Black HR, et al,. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
12. Puzenat E, Bronsard V, Prey S, et al,. What are the best outcome measures for assessing plaque psoriasis severity? A systemic review of the literature. J Eur Acad Dermatol Venereol 2010; 130: 933-943.
13. MacIsaac RJ, Jerums G,. Intensive glucose control and cardiovascular outcomes in type 2 diabetes. Heart Lung Circ 2011; 20: 647-654.
14. Badr D, Kurban M, Abbas O,. Metformin in dermatology: an overview. JEADV 2013; 27: 1329-1335.
15. Tuomilehto J, Lindström J, Eriksson JG, et al,. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
16. Ridker PM, Danielson E, Fonseca FA, et al,. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.
17. Law MR, Morris JK, Wald NJ,. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
18. Langsted A, Freiberg JJ, Nordestgaard BG, et al,. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008; 118: 2047-2056.